Substantial sun exposure and numerous genetic factors, including skin type and family history, are the most important melanoma risk factors. Familial melanoma, which accounts for <10% of cases, is associated with mutations in CDKN2A 1 , MITF 2 and POT1 (refs. 3,4). In sporadic melanoma, mutations in BRAF and NRAS predominate and are mutually exclusive. The oncogenic BRAF V600E allele is found in >70% of benign precancerous nevi and half of human melanomas. Preliminary results from a phase III clinical trial testing the selective BRAF inhibitor in patients with BRAF V600E mutations were remarkable with a majority of patients demonstrating clinical response to therapy; however, metastatic melanoma eventually recurred, and drug-resistant clones showed reactivation of the mitogen-activated protein kinase (MAPK) pathway 5 . Over 20% of melanomas harboring BRAF V600E show intratumoral heterogeneity in BRAF V600E protein expression, and neither BRAF V600E expression nor tumor heterogeneity predicts relapse following BRAF inhibitor treatment 6 . Improving the long-term survival of patients with melanoma harboring BRAF V600E mutant tumors will therefore depend on a systematic approach to identify and target genes and pathways that cooperate with BRAF V600E in tumor development 7 .
Substantial sun exposure and numerous genetic factors, including skin type and family history, are the most important melanoma risk factors. Familial melanoma, which accounts for <10% of cases, is associated with mutations in CDKN2A 1 , MITF 2 and POT1 (refs. 3,4) . In sporadic melanoma, mutations in BRAF and NRAS predominate and are mutually exclusive. The oncogenic BRAF V600E allele is found in >70% of benign precancerous nevi and half of human melanomas. Preliminary results from a phase III clinical trial testing the selective BRAF inhibitor PLX-4032 (vemurafenib) in patients with BRAF V600E mutations were remarkable with a majority of patients demonstrating clinical response to therapy; however, metastatic melanoma eventually recurred, and drug-resistant clones showed reactivation of the mitogen-activated protein kinase (MAPK) pathway 5 . Over 20% of melanomas harboring BRAF V600E show intratumoral heterogeneity in BRAF V600E protein expression, and neither BRAF V600E expression nor tumor heterogeneity predicts relapse following BRAF inhibitor treatment 6 . Improving the long-term survival of patients with melanoma harboring BRAF V600E mutant tumors will therefore depend on a systematic approach to identify and target genes and pathways that cooperate with BRAF V600E in tumor development 7 .
Spontaneous melanoma formation is rare in laboratory mice; however, mice engineered to express key mutated oncoproteins, including Braf V600E , recapitulate the genetic and histological hallmarks of human melanoma. In these models, increased MEK-ERK signaling initiates clonal expansion of melanocytes, which is limited by oncogeneinduced senescence, resulting in dysplastic precancerous nevi. Additional cooperating mutations, including loss-of-function mutations in Pten or Cdkn2a 8, 9 , are required for melanoma progression 10 .
Despite years of intense study, there is an incomplete understanding of the genes and genetic networks that drive melanoma development. Sequencing of human melanoma genomes has shown that these tumors have an order of magnitude more somatic mutations than many other solid tumors [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Ultraviolet radiation-induced DNA damage 12, 15, 16, [20] [21] [22] and intrinsic defective DNA repair mechanisms 16 are thought to drive the high mutation rate, which poses a particular challenge in the identification of driver genes in melanoma. There is also evidence of extensive epigenetic alterations 23, 24 and inter-and intratumoral heterogeneity in human melanoma 25 . This surprising complexity suggests that, in comparison to other solid tumors, many more melanoma genomes must be sequenced to find the lowpenetrance mutations that cooperate with drivers such as BRAF V600E to induce melanomagenesis. Furthermore, some key genes may not have somatic mutations (for example, if they are epigenetically altered or acquire copy number alterations) or are infrequently mutated
Transposon mutagenesis identifies genetic drivers of Braf V600E melanoma Figure 1 SB-mediated mutagenesis promotes melanoma formation in Braf V600E mutant mice. (a) Pigmentation changes in SB|Braf mice appear uniform at 25 weeks of age with all 4-OHT-painted surfaces appearing almost completely black; this was most obvious on tail skin in comparing sibling mice. Green, yellow and white asterisks denote Braf, SB|Braf and SB sibling mice, respectively. (b) Image of the underside of a dorsal skin specimen after it was removed during necropsy of an SB|Braf mouse. In wild-type mice, the dorsal skin was uniformly non-pigmented, but many individual black clones of Braf V600E -positive nevi that covered 4-OHT-painted surfaces were found in SB|Braf mice. Scale bar, 5 mm. (c) KaplanMeier survival curves comparing experimental SB|Braf and control sibling SB and Braf mice (log-rank test, P < 0.0001). (for example, PTEN and MITF). Unbiased, genome-wide melanoma gene discovery methodologies are therefore needed to deconvolute the complexity of this deadly cancer.
RESULTS

SB drives melanoma development in Braf-mutant mice
To identify genes cooperating with Braf V600E , we performed an SB mutagenesis screen in mice carrying a conditional Braf V600E allele (Braf CA/+ ) where wild-type Braf is expressed prior to Cre-mediated recombination and mutant Braf V600E is expressed after Cre-mediated recombination. Braf CA/+ mice 26 were crossed to mice carrying an inducible Tyr-cre ERT2 transgene with melanocyte-specific expression 27 to create Tyr-cre ERT2/+ ; Braf CA/+ mutant mice 9 (hereafter, Braf mice; Supplementary Fig. 1a) . Braf mice were then crossed to mice with an inducible SB transposon system 28, 29 to generate SB|Braf mice (Supplementary Fig. 1a ) 30 . The Braf CA and SB transposase alleles were subsequently activated by topical application of 4-hydroxytamoxifen (4-OHT) to dorsal skin after birth 9 (Supplementary Fig. 1b) .
To overcome complications caused by local transposon hopping 31 and achieve genome-wide coverage for SB mutagenesis, we used three different transgenic lines that carried transposon concatamers on different chromosomes (Supplementary Fig. 1d ). SB transposons contain an internal promoter and downstream splice acceptor site, which can activate expression of proto-oncogenes, and splice acceptor sites in both orientations and a bidirectional polyadenylation sequence, which can inactivate expression of tumor-suppressor genes (TSGs). In total, 13 cohorts of mice, carrying different allele combinations, were aged for the development of cutaneous melanoma ( Supplementary  Figs. 1b,c and 2) .
By the time the mice reached 8-10 weeks of age, we observed hundreds of hyperpigmented nevi on 4-OHT-treated skin. By 25 weeks of age, all painted surfaces appeared uniformly black (Fig. 1a) , whereas, at necropsy, imaging the underside of the dorsal pelt showed many individual clones of pigmented nevi (Fig. 1b and Supplementary  Fig. 3a-c) . All SB|Braf mice developed nevi, and 80% developed one to four tumor masses on 4-OHT-treated dorsal skin, with an average latency of 36 weeks (Fig. 1c) . Tumor penetrance and latency were similar for all three transposon transgenic lines, and the data were therefore combined for subsequent analyses (Supplementary Table 1 ). In contrast, Braf mice developed nevi but no melanomas, whereas SB-only mice did not develop nevi or melanomas ( Supplementary  Fig. 1 ). Taken together, these data show that SB cooperates with Braf V600E to drive melanoma progression.
SB|Braf mice developed amelanotic melanomas with nerve sheath differentiation (Fig. 1d-f and Supplementary Fig. 3d-f) , and the tumors had morphological characteristics ranging from spindle-shaped to round, plump cells with abundant pale eosinophilic cytoplasm. Individual tumors were pleomorphic and often showed all morphological patterns, suggesting that there was extensive inter-and intratumoral heterogeneity. Melanomas were generally dermal or subcutaneous and did not show junctional melanocytic proliferation. In one instance, melanoma cells invaded the body wall ( Supplementary Fig. 3g-i) . Tumor cells generally expressed S-100 and sometimes contained melanin ( Fig. 1g and Supplementary Fig. 3j ) or normal melanocyte antigens ( Fig. 1h and Supplementary Fig. 3k ). SB transposase protein was expressed within tumor cells ( Fig. 1i and Supplementary Fig. 3l ).
Common transposon insertion sites in melanomas
We sequenced the SB insertion sites from 77 melanomas using the 454 Splink method 32, 33 ( Supplementary Fig. 1d , Supplementary Table 1 and Supplementary Note), generating 184,371 mapped reads corresponding to 35,908 non-redundant transposon insertions. We then identified common transposon insertion sites (CISs) using the Gaussian kernel convolution (GKC) 33 and gCIS 34 methods, as described 35 ( Supplementary Figs. 4 and 5, and Supplementary Note). The concordance between the genes identified by both methods was high Fig. 6a-c) , and the methods together identified 1,232 SB|Braf CIS genes (Supplementary Table 2 ). In previous studies, Karreth et al. 36 used SB mutagenesis to identify 36 statistically significant CISs that acted as putative Pten competing endogenous RNAs (ceRNAs). Our screen identified 72% (26/36) of these Pten ceRNAs 36 ; however, we did not observe a significant enrichment for these ceRNAs among our CIS genes (P > 0.05). In a separate study, Ni et al. 37 identified five CIS genes using PiggyBac transposon mutagenesis. Our screen identified three of these genes and paralogs of the other two genes.
More than ~95% of CCGs were predicted to be TSGs ( Supplementary  Fig. 7a ,b, Supplementary Table 2 and Supplementary Note), similar to findings in other reported SB studies 35 , and many of these genes are likely to function as haploinsufficient TSGs. This observation is consistent with studies showing that loss-of-function mutations in hundreds of genes, many of which likely function as haploinsufficient TSGs, can provide a growth advantage to telomerase-immortalized human mammary epithelial cells 38, 39 . These data support the notion that cumulative haploinsufficiencies in many TSGs maximize proliferative fitness in cancer cells.
To investigate whether mutagenic mechanisms other than SB mutagenesis might contribute to SB|Braf melanomagenesis, we used whole-exome sequencing to characterize eight SB|Braf melanomas (six tumor-normal pairs and two tumor-only samples) (Online Methods and Supplementary Table 3 ). Whole-exome sequencing identified 52 genes with significant single-nucleotide variant (SNV) or indel alterations (Bonferroni-corrected P value < 0.05; Fig. 2a and Supplementary Tables 4-7), 6.5 ± 4.7 protein-altering point mutations per tumor genome (far fewer than reported for mouse small-cell lung carcinoma 40 ), and there was no evidence for a mutation signature (Fig. 2b,c) . We identified nine indel mutations (Supplementary Table 8 ) resulting from TACAG or TACTG insertions, which are the canonical SB mutagenic footprints resulting from SB remobilization 41 . We also identified 177 copy number variation (CNV) regions from the 6 tumor-normal genomes, including 130 CNV losses and 47 CNV gains (Supplementary Table 9 ). No genes mapping to these CNVs were recurrently mutated; as a result, their relevance remains unclear (Supplementary Table 10 ). We did, however, observe recurrent focal deletions at three loci, which harbored four CISs-Cep350, Cdkn2a-E130114P18Rik and Slc9a9 (Supplementary Fig. 8a-f) . We also observed recurrent focal amplification in five genomes on distal chromosome 12, a region that contains Adam6a and Adam6b (Supplementary Fig. 8a-f) . Finally, we identified 455 SB insertions that occurred within or at the junctions of exons (Supplementary Table 11 ). Cep350 was mutated in five of the eight genomes and was the only significantly mutated CIS gene identified in these melanoma genomes (q = 2.59 × 10 −269 ; Supplementary Table 11) . Together, our data suggest that SB mutagenesis is the predominant driving force in SB|Braf tumors, with less than the expected contributions from other types of variation normally observed in tumors without induction of SB (ref. 40 Tables 12b  and 13 ). The orthologs of four CIS genes (Cdkn2a, Gnaq, Mitf and Pten) also have known causal roles in human melanoma, the human orthologs of eight CIS genes (Csmd3, Epha6, Erbb4, Adgrv1 (Gpr98), Grm8, Lrp1b, Pkhd1 and Ptprd) are recurrently mutated in human melanoma [15] [16] [17] [18] [19] [20] [21] [22] and the human orthologs of five CIS genes (Ankhd1, Cct3, Gna12, Scamp2 and Slc12a7) contribute to melanomaspecific fusion transcripts 11 . In addition, of the 106 genes containing intragenic rearrangements in 2 or more melanomas 12 , 33% were CCG orthologs (RBFOX1 (A2BP1), CSMD1, FHIT, MACROD2 and MAGI2; P = 4.97 × 10 −11 ; Supplementary Table 12c ). Together, these data suggest a key role for SB|Braf CCGs in human melanomagenesis.
Branching tumor evolution complicates efforts to implement personalized medicine and suggests that targeted therapies might be better directed against genes mutated at the trunk of the cancer evolutionary tree, as these genes are mutated in a high proportion of tumor cells 43 . On the basis of sequencing read counts, we identified 21 genes that appeared to be drivers of early progression in Braf V600E melanomas (Fig. 3a) . These genes included the orthologs of two human melanoma drivers (Cdkn2a and Gnaq), three non-melanomic cancer drivers (Crebbp, Pten and Lpp; Cancer Gene Census, P = 1.54 × 10 −4 ), a gene essential for Wnt signaling in colorectal cancer (Tnik) 44 , two regulators of Hedgehog signaling (Gli3 and Tead1) and a centrosomal protein that recruits FOP-FGFR1 to centrosomes in myeloproliferative
SNV nonsynonymous Indel in frame npg disease (Cep350) 45 . Notably, 70% of all tumors had an insertional mutation in at least one of these 21 genes (Fig. 3b) . We next employed several complementary cross-species oncogenomic approaches to gain further insight into the biological and clinical relevance of the SB|Braf CIS genes in human melanoma. We compiled a list of genes with sequence alterations in 347 human melanomas identified by sequencing whole genomes 14, 18, 23 , exomes 13, 17, [20] [21] [22] 24 or RNA 46 (Supplementary Table 14) . We focused on genes that were mutated in ≥5% of melanomas and considered all mutations in each gene as a single mutation event to avoid the over-representation of genes containing more than one mutation. Overall, 3,577 genes were mutated in ≥5% of melanomas, and each gene had ≥18 somatic mutation events. We found a significant enrichment of SB|Braf CIS genes among these genes (P = 6.76 × 10 −21 ; Supplementary Table 14) . Remarkably, 8.7% of the SB|Braf CIS genes were among the top 10% of the most frequently mutated genes in human melanoma (≥34 somatic mutations per gene, n = 104; P = 4.20 × 10 −11 ) ( Table 1) .
We also compared our list of CIS genes to melanoma susceptibility loci defined by genome-wide association studies (GWAS) and CNV associations (Supplementary Table 2 ). Twenty-two CIS genes mapped to 16 GWAS loci [46] [47] [48] [49] [50] [51] [52] [53] (Supplementary Table 2 ). An additional 398 CIS genes mapped to recurrent chromosomal imbalances in human melanoma genomes: 220 genes mapped to chromosome losses on 1p, 8p, 9p, 10p, 14q, 16q, 17p and 22q, whereas 178 genes mapped to chromosome gains on 3p, 7p, 7q, 8q and 17q (ref. 54 ; Supplementary Table 15) .
Long noncoding RNAs (lncRNAs) are also important genetic elements that may become deregulated by somatic mutations and contribute to disease [55] [56] [57] . We identified 113 CCGs with at least one lncRNA transcript embedded within the coding sequence (Supplementary Table 16 ) and significant enrichment of CIS genes with genes harboring one or more lncRNAs 58, 59 (P = 9.46 × 10 −29 ; Supplementary  Table 12d ). These data suggest that there might be additional layers of gene regulation in these regions, perhaps epigenetic in nature, which control TSG activity.
Several statistical approaches have been developed to identify highconfidence driver genes in tumor genomes [60] [61] [62] . We identified 27 CIS genes within JISTIC-defined susceptibility loci 63 , including 5 deleted (12 CIS genes) and 9 amplified (15 CIS genes) regions, from 123 human short-term melanoma cultures 61 (P = 0.014; Supplementary  Table 12e ). In addition, 49 CIS genes were JISTIC-defined candidate drivers in melanoma (P = 1.16 × 10 −3 ), and 8 were CONEXIC-defined modulators in melanoma (P = 1.69 × 10 −5 ; Supplementary Table 12f) , including the known melanoma drivers Mitf, Grb2 and Tbc1d16. Furthermore, 16 CIS genes mapped to regions of focal deletion (10 CIS genes from 8 loci) or amplification (6 CIS genes from 5 loci) from 31 human melanoma cell lines containing a BRAF V600E mutation 62 (P = 1.69 × 10 −5 ; Supplementary Table 12g) . Taken together, >300 SB|Braf CIS genes map to susceptibility regions in human melanoma (Supplementary Table 2 ).
Conserved altered pathways in melanoma
To gain insight into the biological function of CIS genes, we used the Ingenuity Pathway Analysis (IPA), Database for Annotation, Visualization and Integrated Discovery (DAVID) 64 , Kyoto Encyclopedia of Genes and Genomes (KEGG) 65 and GeneSetDB 66 analysis platforms. We found significant enrichment of CIS genes in many cancer-related signaling pathways and biological processes, including Wnt/β-catenin, transforming growth factor (TGF)-β, phosphoinositide 3-kinase (PI3K) and MAPK signaling and biological (1) MBM0012 (11) MBM0133 (1) MBM0017 (6) (67) MBM0128 (34) MBM0096 (59) MBM0123 (6) MBM0122 (9) MBM0129 (3) MBM0153 (22) MBM0013 (85) MBM0001 (201) MBM0007 (109) MBM0130 (83) MBM0057 (136) MBM0062 (2) MBM0105 (78) MBM0136 (60) MBM0143 (78) MBM0135 (5) MBM0124 (19) MBM0058 (12) MBM0063 (3) MBM0134 (4) MBM0121 (2) MBM0104 (21) MBM0103 (1) MBM0018 (10) MBM0025 (8) MBM0149 (2) MBM0137 (4) MBM0097 (7) MBM0125 (1) MBM0106 (1) MBM0068 (1) MBM0102 (2) MBM0141 ( Fig. 10a ). Among the 21 SB|Braf drivers of early progression (Fig. 3a) Fig. 10b ). Twelve genes with roles in glutamate receptor signaling (GO:0007215) were also collectively altered in >50% of SB|Braf melanomas. Although this finding did not reach statistical significance (false discovery rate (FDR)-adjusted P = 0.1580), it does provide further evidence that glutamate receptor signaling may have a role in melanoma 22 . SB|Braf CIS genes were also enriched for transcription factors (n = 158, P = 7.67 × 10 −3 ; Supplementary Tables 12h and 18 ). Using DAVID, we identified 15 transcription factors whose binding sites were enriched in the promoters of SB|Braf CIS genes (Supplementary Table 19 ). Remarkably, these 15 transcription factors were predicted to bind to 91% of CIS loci (Supplementary Fig. 10 ). CIS genes were also enriched for genes encoding phosphoproteins (59%, n = 717; P = 5.51 × 10 −88 ) and genes known to undergo alternative splicing (41%, n = 499; P = 1.81 × 10 −46 ; Supplementary Table 20) . Collectively, these results suggest that CIS genes function in large signaling networks that can be deregulated at multiple levels and identify a number of signaling networks that should be further evaluated in human melanoma.
CIS interaction networks in melanoma
To further explore the potential interaction networks among CIS genes, we searched for functional links between these genes using a database of human molecular interactions (Online Methods). CIS genes were more functionally connected to one another than expected by chance (empirical P = 0.0043); 1,281 functional links could be drawn between CIS genes, and 352 CIS genes had a functional biological connection to one or more other CIS genes ( Supplementary Fig. 11a and Supplementary Table 21 ), suggesting that SB mutagenesis enriches for mutations affecting functionally interacting proteins. Fifteen highly connected CIS genes had ≥19 functional connections with other CIS genes (Fig. 4a-c and Supplementary Fig. 11b ).
Approximately 47% of SB|Braf melanomas (Fig. 4d) and >30% of human melanomas had one or more SB insertions or somatic mutations, respectively, in genes that function in netrin signaling, a pathway involved in mediating axonal guidance ( Supplementary  Fig. 12) . A significant enrichment for mutations in axonal guidanceassociated genes has also recently been observed in pancreatic cancer 67 . The netrin-1 receptor Dcc was mutated in 24% of SB|Braf melanomas but was not detected by CIS analysis, possibly because it is a large gene. Frequent mutations in DCC have also been identified in human melanomas 14 , raising the possibility that pharmacological inhibition of downstream effectors of netrin signaling could be of clinical benefit for patients with melanoma.
Human melanomas frequently contain mutually exclusive mutations in Rho family members 13 . We identified five Rho family members (Rac1, Rhoa, Rhot1, Cdc42bpb and Cdc42se2) that were mutated in a mutually exclusive manner in 23% (16/70) of the SB|Braf melanomas (Fig. 4e) , providing additional support for the hypothesis that corresponding mutations are important in human melanoma. 
A r t i c l e s
This result is also consistent with observations of a mutually exclusive relationship between Rac and Rho signaling in the control of movement in a three-dimensional culture model of melanoma metastasis 68 . Extension of this analysis to other protein-coding families also identified mutually exclusive mutations among members of the SWI/SNF chromatin-remodeling complex and NFAT family members ( Supplementary Fig. 13a,b and Supplementary Note). Together, our data demonstrate a systems network of deregulated pathways that contribute to melanoma progression. Next, we assessed the clinical relevance of the SB|Braf CIS genes using microarray data for which corresponding patient survival data were available (Gene Expression Omnibus (GEO), GSE19234) 69 . We considered a gene to have been validated if there was at least one probe on the array that showed a significant association with patient survival using Cox proportional hazards (CPH) regression. We found 322 CIS genes significantly associated with patient survival (P < 0.05; Supplementary Table 2 ). However, after corrections for multiple testing, only 46 genes remained significant (FDR-adjusted P < 0.01; Supplementary Table 22) . At this significance cutoff, the number of prognosis-associated genes (46/1,139) was more than would be expected by chance from random lists of a similar size (Fisher's exact test, P = 0.04). Representative survival plots and log-rank survival data for these genes are shown in Figure 5a-c, Supplementary  Figure 14 and Supplementary Table 2. CIS interaction network analysis showed that 12 of these genes were highly connected (Fig. 5d) . To our knowledge, this is the first report identifying ANKRD40, SDK1, THSD7B, DOCK5, GRIA3, ITCH, KDM4C, LPP, MAGI2, MYO10, NCOA3 and PRUNE as candidate tumor suppressors and GART as a candidate oncogene in predicting human melanoma survival outcomes.
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A r t i c l e s CEP350 has a role in human melanoma progression Among the three highest ranked CIS genes, Cep350 is the only one not causally implicated in human melanoma. Cep350 is a predicted TSG on the basis of the transposon insertion pattern and the finding that Cep350 is one of only four genes identified by whole-exome sequencing to be mutated in more than one melanoma (MBM0001 and MBM0014; Supplementary Fig. 8a,c) . Thirty-seven percent of SB|Braf melanomas had >1 SB insertion in Cep350 (33 SB insertions in 19 genomes). Cep350 may therefore represent a classical TSG. Alternatively, multiple Cep350 insertions in the same tumor could reflect tumor heterogeneity and convergent evolution. CEP350 was mutated in 7.2% of human melanoma genomes (n = 25), and these mutations included multiple stop-gain and missense mutations that were predicted to have damaging effects on CEP350 expression-features consistent with a putative role for CEP350 as a human melanoma TSG (Fig. 6a) .
To determine whether CEP350 is a human melanoma TSG, we used stable short hairpin RNA (shRNA)-mediated knockdown of CEP350 in two well-characterized human melanoma cell lines, A375 and COLO829 (refs. 11,16) , which each harbor a BRAF V600E mutation. We found robust CEP350 expression in unmodified A375 and COLO829 cells and observed no significant difference in CEP350 expression after lentiviral transduction with control shRNA. Lentiviral transduction of A375 and COLO829 cells (multiplicity of infection (MOI) of 6) with either pooled or individual nonoverlapping CEP350 shRNAs reduced CEP350 expression levels by ~50% (Supplementary Fig. 15a,b) . For both cell lines, subcutaneous injection of cells into immunodeficient mice resulted in enhanced in vivo tumor formation with CEP350 depletion (Fig. 6a-e and Supplementary Figs. 16 and 17) , providing functional evidence that CEP350 is a human melanoma TSG.
DISCUSSION
In the studies presented here, we describe a transposon-based screen in mice aimed at identifying genes that cooperate with BRAF V600E in melanoma induction. Transposons, by their nature, are well suited to capture the full complement of genetic complexity present in tumor cells because they can identify genes that are somatically mutated in human cancer in addition to genes that are deregulated by transcriptional or epigenetic means. We also examined the entire spectrum of somatic mutations in SB-induced tumors by whole-exome sequencing.
To our knowledge, this is the first time that SB-induced tumors have been characterized by whole-exome sequencing. Reassuringly, we found that the cumulative burden from SB mutagenesis was significantly higher and disproportionate to the number of non-SB mutagenic events, strongly suggesting that SB mutagenesis largely drives melanomagenesis in this model. The vast majority of the genes identified in our screen were putative haploinsufficient TSGs. Over-representation of TSGs is an emerging, latent feature that is shared by all SB screens reported thus far for solid tumor types. Cumulative haploinsufficiencies in hundreds of genes have also been shown using human cancer cell lines 39 and may thus be a general mechanism through which cancer evolves. CIS genes also had more functional connections to one another than predicted by chance. In addition, there was a significant enrichment for transcription factors among CIS genes, and DNA binding sites for these transcription factors were significantly enriched in the promoters of CIS genes. Collectively, these results suggest that genes identified by SB function in large signaling networks that can be deregulated at multiple levels.
A surprising result from our study was that BRAF V600E -mutated and BRAF-wild type human melanomas were similarly enriched for mutations in SB|Braf CIS genes. Examination of human melanoma genomes sequenced by The Cancer Genome Atlas (TCGA) 13 shows that 70% of all melanomas without mutated BRAF have an oncogenic point mutation in NRAS, highlighting the importance of MAPK pathway activation in melanomagenesis. Thus, 87% (105/121) of TCGA melanoma genomes contain BRAF or NRAS mutations 13 . A likely explanation for our findings is that SB screening identifies genes that cooperate with MAPK pathway activation rather than mutant BRAF V600E per se, with this activation occurring at a high frequency in both BRAF V600E -mutated and BRAF-wild type human melanomas. Thus, a notable finding of our study is that the CIS genes identified High (19) Low (19) Log-rank P < 0.001 High (19) Low (19) Log-rank P = 0.011 High (19) Low ( by SB mutagenesis are operative in both BRAF V600E -mutated and BRAF-wild type human melanomas. Forty-six SB|Braf CIS genes were also identified as having potential value in predicting human patient survival outcomes. Interaction network analysis showed that 12 of these genes have a large number of connections to other genes identified in our forward genetic screen. This suggests that pathway deregulation via alterations in networks of genes may drive tumor progression and contribute more to melanomagenesis than any single or few genetic or epigenetic alterations. Support for this hypothesis is observed in the rapidly acquired resistance to BRAF V600E -targeted therapies by patients carrying BRAF V600E mutations and the nearly 20% of patients with BRAF V600E mutations who are non-responders.
A major finding of our screen was the identification of CEP350 as a new candidate human melanoma TSG. CEP350 is a CAPGly-containing protein predicted to participate in organizing, binding and anchoring microtubules at centrosomes by binding to SASS6 and CENPJ in a complex 70 . CEP350 may also have a non-centrosomal role in regulating nuclear hormone receptor signaling [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] . A role for CEP350 in human melanoma was also suggested by a recent report of a familial melanoma susceptibility locus 3 that mapped near CEP350. We demonstrate that shRNA-mediated knockdown of CEP350 in the human melanoma cell lines A375 and COLO829 significantly accelerates tumor growth in xenograft assays. Of note, both cell lines harbor BRAF V600E mutations in addition to mutations in CDKN2A and PTEN. Interestingly, Cep350 and Cdkn2a were identified as CIS genes only in SB|Braf V600E melanoma (M.B.M., J.Y.N., N.G.C. and N.A.J., unpublished data). This suggests that, whatever tumor-suppressive role Cep350 and Cdkn2a might have in tumorigenesis, it is likely to be dependent on cooperation with oncogenic Braf.
Our integrated studies suggest that melanoma is a systems biology problem. As predicted by the systems nature of these tumors, we found that SB|Braf CIS genes are more highly connected to one another through functional molecular links than would be predicted by chance. This observation supports the hypothesis that cancer therapies should be directed against signaling pathways themselves rather than individually mutated genes. However, exactly where to intervene in the genetic network is not a trivial problem, considering the likely presence of complex combinations of regulatory feedback loops, as has been observed from the contrasting therapeutic effects of vemurafenib on BRAF-mutated melanoma and colorectal cancer 85 . With only a limited amount of preexisting information, the simplest method would be to disrupt genetic network connectivity by attacking its major hubs 86 , as these proteins are most essential for cellular function. Removing a hub from the network would be predicted to drastically change the network signaling properties and connectedness to other parts of the network. The melanoma CIS genes identified here, including those with high connectivity to other genes in the network, provide a rich new resource of candidate genes for melanoma progression and drug targeting, in addition to a list of biological pathways and cellular processes with potential clinical importance in the treatment of human melanoma. primers obtained from PrimerBank 97 : CEP350-F (PrimerBank, 171184450c2), CEP350-R (PrimerBank, 171184450c2), RPL13A-F (PrimerBank, 6912634a1) and RPL13A-R (PrimerBank, 6912634a1). All qRT-PCR data are reported as ∆∆C t values. Xenograft measurements were taken at least twice weekly using digital calipers while mice were conscious but restrained by one experimenter familiar with collecting caliper measurements of xenografts and blinded to the experimental group designations. GFP fluorescence was visualized at the time of caliper measurement; loss of GFP signal was considered to indicate failed engraftment, and corresponding mice were removed from the study (take rates were ≥80% for all cohorts). Ellipsoid tumor volumes were calculated as volume (mm 3 ) = 0.52(length (mm) × width 2 (mm 2 )), where the two longest axes, length and width, were the major and minor diameter measurements, respectively; width 2 represents an assumption that the xenograft depth was equivalent to the diameter of the minor axis 98 . Statistical significance of tumor volumes at defined time points was determined by either one-way t test for all cohorts relative to shNTC or by two-way, repeated-measures ANOVA with Bonferroni correction for multiple comparisons, as indicated. Area under the curve (AUC) calculations were used to estimate the magnitude of effect from cumulative growth curves. Kaplan-Meier survival curves plot the results of experiments where the outcome was time until death (days after injection to necropsy); the statistical significance for survival disparity was calculated using the log-rank (Mantel-Cox) test. Necropsy of xenograft-bearing mice was conducted by trained staff blinded to the experimental study design and included processing of end-stage xenograft masses and specimen archiving by cutting the xenograft masses into two halves, with one half fixed in formalin for histological analysis and the second half flash frozen in liquid nitrogen. For a subset of necropsy specimens, qRT-PCR analysis for human CEP350 and RPL13A was performed to assess the levels of knockdown of individual clones contributing to in vivo tumor growth. All xenograft work was approved by the Institutional Animal Care and Use Committee at the Houston Methodist Research Institute.
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